There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TG Therapeutics (TGTX), Checkpoint Therapeutics Inc (CKPT) and uniQure NV (QURE) with bullish sentiments.
TG Therapeutics (TGTX)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TG Therapeutics, with a price target of $20. The company’s shares closed on Friday at $7.56.
White observed:
“Our $20 price target is based on the net present value of our revenue forecast through 2027, applying a 40% probability of success (POS) for ublituximab in CLL, a 40% POS for umbralisib in CLL, a 30% POS for ublituximab in NHL, a 45% POS for umbralisib in 40% POS for ublituximab in MS. We use a 4x price/sales multiple for these products, an early stage pipeline value of $0.26/share, which includes an anti-PD-L1 drug, an oral BTK inhibitor, and a CD47/CD19 bispecific antibody, and our year-end 2019 net cash estimate of $0.29 to arrive at our price target.”
According to TipRanks.com, White is a 5-star analyst with an average return of 15.3% and a 48.7% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Aileron Therapeutics Inc.
Currently, the analyst consensus on TG Therapeutics is a Strong Buy with an average price target of $17.33, which is a 129.2% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $17 price target.
See today’s analyst top recommended stocks >>
Checkpoint Therapeutics Inc (CKPT)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Checkpoint Therapeutics Inc, with a price target of $15. The company’s shares closed on Friday at $5, close to its 52-week high of $5.20.
Pantginis noted:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $15 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s two lead assets, cosibelimab and CK-101. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis is a 2-star analyst with an average return of 0.0% and a 36.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Armata Pharmaceuticals Inc.
Checkpoint Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $15.
uniQure NV (QURE)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on uniQure NV, with a price target of $73. The company’s shares closed on Friday at $61.10.
Chattopadhyay observed:
“Our $73 price target is based on a 12-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130. For AMT-061, we assume a 70% POS driven by the compelling clinical updates and single- arm Phase 3 involving about 50 patients, along with RMAT and PRIME designations. We anticipate commercial launch during uniQure N.V. May 13, 2019 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 22H22, with a NAB-based exclusion of 5%, and model risk-adjusted peak sales of roughly $900M, during 2028.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.8% and a 46.6% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Autolus Therapeutics Plc.
uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $78.67, which is a 28.8% upside from current levels. In a report issued on April 29, B.Riley FBR also reiterated a Buy rating on the stock with a $72 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
